GE HealthCare has launched new editions of its three invasive cardiac software solutions.
Applying to the medtech giant’s Mac-Lab, CardioLab, and ComboLab solutions, the AltiX AI.i software upgrades gained US Food and Drug Administration (FDA) clearance in December 2024 and aim to improve user experience and workflows, as well as support complex electrophysiology (EP) procedures.
Go deeper with GlobalData
The AltiX AI.i edition of Mac-Lab builds on the cardiac catheterisation software’s ability to capture diastolic hyperaemia-free ratio (DFR) measurements with the integration of an algorithm for measuring the diastolic pressure ratio (dPR). The measurements are used to determine the severity of coronary artery disease (CAD).
Used in EP procedures, the AltiX AI.i edition of CardioLab improves the software’s ability to visualise physiological signals with the addition of the Prucka 3 digital amplifier to reduce environmental noise and maintain “high signal fidelity”. Designed to help clinicians diagnose and treat cardiac arrhythmias, Prucka 3 was first unveiled in January 2024.
The upgraded edition of CardioLab also showcases the integration of Volta Medical’s AI-based decision support system, Volta AF-Xplorer, into the EP solution, bringing to fruition a joint development agreement the companies forged in 2024.
Prucka 3’s PruckaStream function transmits real-time data to Volta’s system, a feature GE HealthCare said is designed to support clinicians in making real-time assessments when using AI to evaluate areas believed to initiate or maintain atrial fibrillation drivers in EP procedures.
The AltiX AI.i revision to ComboLab, GE Healthcare’s all-in-one recording software for cardiology means that EP and haemodynamic recording are now integrated into a single system, offering “versatile functionality” for cath lab procedures and EP exams.
GE HealthCare interventional solutions general manager Arnaud Marie said AltiX AI.i “reinforces” the company’s commitment to advancing cardiac care.
Marie said: “These improved solutions are designed to enhance diagnostic and therapeutic capabilities, which are crucial for diagnosing and treating various heart conditions.
“This launch is an important step in our ongoing mission to equip healthcare providers with interventional solutions that evolve alongside their needs.”
GE HealthCare plans to showcase the AltiX AI.i software editions at the European Heart Rhythm Association (EHRA) 2025, taking place from 30 March to 1 April in Vienna, Austria; and at the Heart Rhythm Society (HRS) 2025 on 24-27 April in San Diego, US.
AltiX AI.i is available for order in the US and will launch in global markets later this year.
According to GlobalData analysis, the EP diagnostic catheter market in the US is expected to grow at a CAGR of 10% between 2024 and 2033, with continued innovations and cost-effective solutions expected to address the market barriers and sustain long-term expansion.
